Bruker Corporation logo BRKR - Bruker Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 17
HOLD 14
SELL 2
STRONG
SELL
0
| PRICE TARGET: $52.17 DETAILS
HIGH: $70.00
LOW: $35.00
MEDIAN: $51.50
CONSENSUS: $52.17
DOWNSIDE: 11.98%

About Bruker Corporation (https://www.bruker.com)

Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.

Key Executives

NAME TITLE DOB SALARY
Frank H. Laukien Chairman, Chief Executive Officer & President 1960 $1,594,872 USD
Mark R. Munch Corporate Executive Vice President and President of Bruker Nano Group & Corporate 1962 $1,119,503 USD
Gerald N. Herman Executive Vice President & Chief Financial Officer 1959 $879,311 USD
Falko Busse President of Bruker BioSpin Group 1967 $822,109 USD
Juergen Srega President of Bruker CALID Group & Bruker Daltonics Division 1955 $772,590 USD
Burkhard Prause President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc. 1967 $595,963 USD
J. Brent Alldredge Senior Vice President, General Counsel, Secretary & Global Head of Compliance 1975
Thomas Bures Chief Accounting Officer 1975

Company Peers

Peer analysis pending, check back in 1-2 minutes.